BiomeBank

What BiomeBank does

BiomeBank is a clinical-stage biotechnology company headquartered in Adelaide, South Australia, developing microbiome-based therapeutics to treat diseases linked to gut microbial dysbiosis. Its commercial product, BIOMICTRA, received world-first TGA approval in November 2022 as a donor-derived faecal microbiota transplantation (FMT) therapy for recurrent Clostridioides difficile infection, and is sold directly to licensed medical practitioners and hospitals across Australia via a quote-based direct sales model with cold-chain (dry-ice) logistics. The company also operates the proprietary CONSORTIOME platform — a co-culturing system that generates synthetic human gut microbial communities in bioreactors containing over 90% of known gene families in a healthy microbiome — supported by one of the world's largest culture collections of human gut microbes (35,000+ bacteria, 900 species) and machine learning-guided strain identification.

BiomeBank's pipeline includes BB265 (a CONSORTIOME-engineered cultured therapy for ulcerative colitis, in Phase 1b/2a trials from 2025), BB128 (for an orphan disease indication), and a planned oral capsule reformulation of BIOMICTRA targeted for 2026 launch. Revenue mechanics span pharmaceutical product sales to Australian healthcare providers, future cultured therapy sales from pipeline approvals targeting a $13B US ulcerative colitis TAM by 2032, and consumer wellness products to be distributed through a strategic partnership with Blackmores Group announced April 2026 with up to AUD $15 million in funding. The company operates from a purpose-built GMP manufacturing facility opened in Adelaide's biomedical precinct in November 2023, has raised more than AUD $25 million cumulatively across venture rounds, government grants, and strategic investment, and has stated headcount growth from 18 to 32 with further hiring planned.

The company is led by co-founder and CEO A/Prof Sam Costello alongside co-founders Prof Rob Bryant (VP Clinical Translation), Dr Emily Tucker (Head of Medical Affairs), and A/Prof Sam Forster (Chief Scientific Officer), with Chris Hall (former CIO of Ellerston Capital) serving as Non-Executive Chairman. The investor base includes The Hospital Research Foundation Group (founding seed investor), Artesian Alternative Investments/South Australian Venture Capital Fund, North South Ventures (US), Ellerston Capital, and Blackmores Group/Kirin Health Science International. Current commercial revenue is concentrated on Australian hospitals and licensed practitioners, with stated intent to expand into Asia Pacific markets and consumer health segments through the Blackmores partnership.

Name

BiomeBank

Legal name

COST-BRY Pty Ltd ACN 630 632 610 (trading as BiomeBank)

Website

https://biomebank.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

BiomeBank is an Adelaide-based clinical-stage biotechnology company developing microbiome-based therapeutics, including the world's first TGA-approved donor-derived FMT therapy (BIOMICTRA) and a proprietary CONSORTIOME platform for next-generation cultured microbiome products targeting gastroenterology, IBD, and consumer wellness markets.

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Fecal Microbiota Transplantation (FMT) & Microbiota Restoration Products (HLAAAFAE)

akta.pro secondary industries

Consortia & Defined Microbial Community Therapeutics (HLAAAFAC), Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK), Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD)

Keywords

• Microbiome therapeutics
• Live biotherapeutic products
• Gut microbiota restoration
• Faecal microbiota transplantation
• Cultured microbial therapies

Headquarters

HQ city

Adelaide

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. BIOMICTRA® Product Sales: BiomeBank generates revenue from the sale of its ARTG-listed donor-derived microbiome therapy BIOMICTRA® to licensed medical practitioners, hospitals, and clinics throughout Australia. The product is sold in frozen syringe formulations for colonoscopy and enema delivery. Capsule reformulation is planned to improve patient access and expand market reach. Revenue is derived from direct commercial transactions with healthcare providers, with pricing varying by location, dosage, and delivery requirements.
2. Pharmaceutical Pipeline (BB265, BB128): BiomeBank is developing a pipeline of second-generation cultured microbiome therapies (BB265 for ulcerative colitis, BB128 for an orphan disease indication) expected to enter clinical trials. Future revenue will be derived from these therapies upon regulatory approval, targeting large global markets including the US ulcerative colitis market projected to reach $13B annually by 2032.
3. Novel Probiotic Consumer Products: Through the Blackmores strategic partnership, BiomeBank intends to develop next-generation probiotic products for consumer markets. Blackmores' trusted brand, channels to market, and global reach will enable the introduction of probiotic innovations beyond the current pharmaceutical product, potentially extending into consumer-facing wellness products.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

BiomeBank develops and commercializes microbiome-based therapeutics, led by BIOMICTRA, a TGA-approved donor-derived Faecal Microbiota Transplantation (FMT) therapy for treatment of recurrent Clostridioides difficile infection, sold to Australian hospitals and clinics. The company is also developing next-generation cultured microbiome therapies through its proprietary CONSORTIOME platform, including BB265 for ulcerative colitis (in Phase 1b/2a trials) and BB128 for an orphan disease indication.

Product overview

BiomeBank offers a portfolio spanning first-generation donor-derived microbiome therapies and next-generation cultured microbial therapeutics. The current commercial product is BIOMICTRA®, a TGA-approved donor-derived FMT therapy for recurrent C. difficile infection, delivered as a frozen syringe for colonoscopy/enema. This is supported by BiomeBank's proprietary CONSORTIOME® platform, which generates artificial co-cultured human gut microbial communities in bioreactors, containing over 90% of known gene families found in healthy gut microbiomes. From this platform, BiomeBank is developing a pipeline of cultured therapies led by BB265 for ulcerative colitis (Phase 1b/2a trials) and BB128 for an orphan disease indication. A GMP manufacturing facility in Adelaide underpins both current commercial supply and future scaled production. An oral capsule formulation of BIOMICTRA® is planned for launch in 2026.

Differentiator

Problem solved

Functional benefit

Brands

• BIOMICTRA: World's first regulated donor-derived microbiome therapy for treatment of recurrent Clostridioides difficile infection. Listed in Australian Register of Therapeutic Goods (ARTG: 399066).
• CONSORTIOME

Products and services

• BIOMICTRA Donor-derived Faecal Microbiota Transplantation (FMT) product, TGA-approved (ARTG: 399066) for treatment of recurrent Clostridioides difficile infection. Delivered as a frozen syringe formulation for colonoscopy and enema administration, manufactured in a GMP facility from rigorously screened healthy human donor stool. An oral freeze-dried capsule formulation is planned for 2026 to improve patient access.
• BB265 Rationally designed cultured microbiome therapy engineered using the CONSORTIOME platform for treatment of ulcerative colitis. Developed using data from discovery trials with BIOMICTRA donor-derived therapy in patients with active ulcerative colitis. Currently in Phase 1b/2a human clinical trial with lead candidate status for the company's cultured therapy pipeline.

Quantifiable outcome

• Up to 90% success rate in breaking the cycle of reinfection for recurrent C. difficile infection (vs. 27% for antibiotic treatment)
• +6 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Blackmores Group (Kirin Health Science International)coreGTM or Marketing Partner · 17 April 2026Blackmores Group has made an up to $15 million strategic investment in BiomeBank, forming a strategic GTM partnership to develop and commercialize next-generation probiotic innovations. The partnership leverages Blackmores' trusted brand, global channels to market, and natural health heritage with BiomeBank's world-class microbiome research and CONSORTIOME platform. This is Blackmores' first investment under its newly created Kirin Health Science International structure. The partnership targets the global consumer probiotic market and aims to develop products that extend well beyond species currently available.
• CytivacoreTechnology or Integration · 20 February 2024Cytiva, a global leader in life sciences with nearly 15,000 associates in over 40 countries, is partnered with BiomeBank in the CRC-P grant project to develop manufacturing infrastructure for cultured microbial therapeutics in Adelaide. Cytiva provides significant in-kind contributions to the project alongside the Australian Government's $2.1M CRC-P grant, contributing expertise in bioprocessing and manufacturing technology to help BiomeBank scale its microbial therapies to commercially viable volumes.
• St Vincent's Hospital Melbourne and The Queen Elizabeth HospitalsupportingStrategic or Co-development Partner · 8 November 2023BiomeBank partnered with St Vincent's Hospital Melbourne and The Queen Elizabeth Hospital in Adelaide for the Microbial Restoration in Inflammatory Bowel Disease (MIRO) study — the world's first pivotal trial demonstrating microbiome restoration in the treatment of Crohn's disease. The company supplies its approved BIOMICTRA product to support this clinical trial.
• Hudson Institute of Medical ResearchcoreStrategic or Co-development Partner · 26 January 2022A 4-year collaboration agreement signed between BiomeBank and Hudson Institute to discover and develop microbial therapies. BiomeBank gained exclusive license to pediatric IBD study data which identified key bacteria believed to be involved in disease onset and resolution, using a world-first method that unlocks culturing and metagenomics of colon biopsy samples. The partnership leverages Hudson Institute's research capabilities and BiomeBank's translation and development expertise. Hudson Institute researchers (led by A/Prof Sam Forster) have developed one of the world's most diverse collections of human commensal bacteria and detailed understanding of how these may protect against disease.
• RMIT UniversitysupportingStrategic or Co-development Partner · 17 July 2021BiomeBank collaborated with RMIT University researchers (Professor Namita Choudhury, Professor Naba Dutta, and Dr Srinivas Mettu) to develop bioreactor technology for artificial 'super stool' manufacturing. Secured $100,000 in funding from IMCRC (Innovative Manufacturing CRC) to develop the new bioreactor technology using novel hydrogel platforms to grow multiple beneficial bacteria strains simultaneously. The technology replicates the complex community of microbes in the human gut and enables scalable, cost-effective production of cultured microbiome therapies.

Scale indicators11 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Seres Therapeutics: Clinical-stage microbiome therapeutics company that developed VOWST, the first FDA-approved oral microbiome therapeutic for recurrent C. difficile. Direct competitor to BiomeBank's BIOMICTRA in the same indication and pioneering a similar regulatory pathway.
• Vedanta Biosciences: Developer of defined bacterial consortia for immune-mediated diseases, using rationally designed live biotherapeutic products. Closely parallels BiomeBank's CONSORTIOME platform approach of engineering defined microbial communities rather than donor-derived FMT.
• Finch Therapeutics: Microbiome therapeutics developer working on CP101 and other consortia-based therapies for C. difficile and IBD. Operates in the same regulatory and clinical space as BiomeBank's BIOMICTRA and CONSORTIOME-derived candidates.
• MaaT Pharma: European clinical-stage microbiome company developing donor-derived and standardized microbiome therapies for oncology and gut-related diseases. Comparable donor-screening and FMT manufacturing approach to BiomeBank.
• Rebiotix (Ferring): Pioneer in standardized microbiome-based therapeutics, now part of Ferring. Developed RBX2660 (REBYOTA), the first FDA-approved live biotherapeutic for C. difficile — directly comparable to BIOMICTRA's regulatory and commercial positioning.
• 4D Pharma: UK-based clinical-stage microbiome therapeutics company developing live biotherapeutics for cancer, respiratory, and gastrointestinal indications. Direct competitor in the same live biotherapeutic space as BiomeBank's cultured therapy pipeline.

Broad incumbents

• Ferring Pharmaceuticals: Global pharmaceutical company that commercialized REBYOTA, the first FDA-approved fecal microbiota product for recurrent C. difficile (via Rebiotix acquisition). Competes directly with BIOMICTRA in the same indication globally.
• Yakult Honsha: Global probiotic and dairy giant with deep microbiome science capabilities. Represents the consumer health incumbent that BiomeBank's Blackmores partnership aims to compete with through next-generation probiotic products.
• BioGaia: Swedish probiotic company with global consumer health distribution. Comparable through its probiotic product portfolio and emerging microbiome therapeutic initiatives, especially relevant to BiomeBank's consumer health expansion strategy.

Emerging players

• Assembly Biosciences: Biotech developing microbiome-based therapies and antivirals, with intersecting interest in gut-mediated mechanisms. Adjacent therapeutic platform with overlapping scientific foundations in microbial consortia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/BankBiome
• YouTubeyoutube.com/@BiomeBank
• LinkedInau.linkedin.com/company/biomebank
• Instagraminstagram.com/_biomebank/?hl=en

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BiomeBank